Journal
LEUKEMIA
Volume 31, Issue 11, Pages 2279-2285Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2017.229
Keywords
-
Categories
Funding
- American Society of Hematology
- Alex's Lemonade Stand Foundation for Childhood Cancer
- Lauri Strauss Leukemia Foundation
- NRF, Singapore [MOE2014-T3-1-006]
- MOE, Singapore [MOE2014-T3-1-006]
- NCI/NIH [CA66996, CA197697]
- DFG, German Research Foundation [BE 2042/12-1, BE 2042/7-1, GRK1591]
- Deutsche Jose Carreras Leukamie-Stiftung e.V. [DJCLS R 11/17, 7R/2016, R15/18, R12/31]
- Wilhelm Sander Stiftung [2013.153.1, 2015.093.1]
Ask authors/readers for more resources
Myeloid master regulator CCAAT enhancer-binding protein alpha (C/EBP alpha) is deregulated by multiple mechanisms in leukemia. Inhibition of C/EBP alpha function plays pivotal roles in leukemogenesis. While much is known about how C/EBP alpha orchestrates granulopoiesis, our understanding of molecular transformation events, the role(s) of cooperating mutations and clonal evolution during C/EBP alpha deregulation in leukemia remains elusive. In this review, we will summarize the latest research addressing these topics with special emphasis on CEBP. mutations. We conclude by describing emerging therapeutic strategies to restore C/EBP alpha function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
